Tacrolimus (FK506) Limits Accumulation of Granulocytes and Platelets and Protects against Brain Damage after Transient Focal Cerebral Ischemia in Rat(Pharmacology)
スポンサーリンク
概要
- 論文の詳細を見る
We investigated the neuroprotective effect of tacrolimus (FK506) on the ischemia-reperfusion injury caused by transient focal brain ischemia induced by middle cerebral artery (MCA) occlusion for 60min in rats. Neuronal damage visualized as a decrease of MAP2 immunoreactivity was observed in the cerebral cortex at 9h after MCA occlusion and further expanded at 24h. Hypoxic areas visualized with an immunohistochemical reaction for 2-nitroimidazole, a hypoxia marker (hypoxyprobe-1), and accumulation of granulocytes and platelets were also observed at 9h and 24h after MCA occlusion. Tacrolimus (1mg/kg, i.v.), administered immediately after MCA occlusion, attenuated cortical damage and decreased the hypoxyprobe-1 positive area, as well as the number of granulocytes and platelets at 24h after MCA occlusion. Immunohistochemical analysis showed that tacrolimus reduced the number of blood vessels positively stained for ICAM-1, E-selectin and P-selection. These results suggested that tacrolimus limited attachment of granulocytes and platelets to blood vessels by inhibiting the expression of adhesion molecules and protected neuronal tissue from hypoxic insults.
- 社団法人日本薬学会の論文
- 2007-02-01
著者
-
Yanagihara Takehiko
Pharmacology Research Laboratories Astellas Pharma Inc.:astellas Research Institute Of America Llc.
-
NOTO Takahisa
Medicinal Biology Research Laboratories, Astellas Pharmaceutical Inc.
-
FURUICHI Yasuhisa
Medicinal Biology Research Laboratories, Astellas Pharmaceutical Inc.
-
ISHIYE Masayuki
Medicinal Biology Research Laboratories, Astellas Pharmaceutical Inc.
-
MATSUOKA Nobuya
Medicinal Biology Research Laboratories, Astellas Pharmaceutical Inc.
-
ARAMORI Ichiro
Medicinal Biology Research Laboratories, Astellas Pharmaceutical Inc.
-
MUTOH Seitaro
Medicinal Biology Research Laboratories, Astellas Pharmaceutical Inc.
-
YANAGIHARA Takehiko
Osaka Neurological Research Institute
-
Noto Takahisa
Department Of Applied Pharmacology 1 Pharmacology Research Labs Astellas Pharma Inc.
-
Noto Takahisa
Pharmacology Research Laboratories Astellas Pharma Inc.
-
Mutoh Seitaro
Pharmacology Res. Labs Astellas Pharma Inc. Jpn
-
Mutoh Seitaro
Pharmacology Research Labs Astellas Pharma Inc.
-
Yamada Toshiko
Astellas Research Institute Of America Llc.
-
Aramori Ichiro
Molecular Medicine Research Laboratories Astellas Pharma Inc.
-
Ishiye Masayuki
Medicinal Biology Research Laboratories Astellas Pharmaceutical Inc.
-
Matsuoka Nobuya
Medicinal Biology Research Laboratories Astellas Pharmaceutical Inc.
-
Aramori Ichiro
Medicinal Biology Research Laboratories Astellas Pharmaceutical Inc.
-
Mutoh Seitaro
Medicinal Biology Research Laboratories Fujisawa Pharmaceutical Co. Ltd.
-
Furuichi Yasuhisa
Medicinal Biology Research Laboratories Astellas Pharmaceutical Inc.
関連論文
- Novel Method for Selecting Immunosuppressive Histone Deacetylase (HDAC) Inhibitors with Minimal Thrombocytopenia(Molecular and Cell Biology)
- Tacrolimus (FK506) Limits Accumulation of Granulocytes and Platelets and Protects against Brain Damage after Transient Focal Cerebral Ischemia in Rat(Pharmacology)
- An application of a new planar positron imaging system (PPIS) in a small animal : MPTP-induced parkinsonism in mouse
- Unique Properties of Coactivator Recruitment Caused by Differential Binding of FK614, an Anti-diabetic Agent, to Peroxisome Proliferator-Activated Receptor γ(Molecular and Cell Biology)
- FK614, a Novel Peroxisome Proliferator-Activated Receptor γ Modulator, Induces Differential Transactivation Through a Unique Ligand-Specific Interaction With Transcriptional Coactivators
- Efficacy of Oral Treatment With Tacrolimus in the Renal Transplant Model in Cynomolgus Monkeys
- Effect of a New Immunosuppressant Histon Deacetylase (HDAC) Inhibitor FR276457 in a Rat Cardiac Transplant Model(Pharmacology)
- Direct Comparison of the Pharmacodynamics of Four Antifungal Drugs in a Mouse Model of Disseminated Candidiasis Using Microbiological Assays of Serum Drug Concentrations
- Determination of Antifungal Activities in Serum Samples from Mice Treated with Different Antifungal Drugs Allows Detection of an Active Metabolite of Itraconazole
- Implitapide, a Microsomal Triglyceride Transfer Protein Inhibitor, Reduces Progression of Atherosclerosis in Apolipoprotein E Knockout Mice Fed a Western-Type Diet : Involvement of the Inhibition of Postprandial Triglyceride Elevation(Pharmacology)
- Antiemetic Activity of FK1052, a 5-HT_3- and 5-HT_4-Receptor Antagonist, in Suncus murinus and Ferrets
- Pharmacological Characterization of FR194921, a New Potent, Selective, and Orally Active Antagonist for Central Adenosine A_1 Receptors
- Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds
- Antiemetic Activity of FK1052, a 5-HT3- and 5-HT4-Receptor Antagonist, in Suncus murinus and Ferrets
- Pharmacological Characterization of FR194921, a New Potent, Selective, and Orally Active Antagonist for Central Adenosine A1 Receptors